Table 4.
Summary of ATPS-based biomaterials with simple structures for drug delivery.
| ATPS-based biomaterial used for drug delivery | Delivered component | The ingredient of the ATPSs | The advantage of the materials obtained | Ref. |
|---|---|---|---|---|
| (1) Natural macromolecular monomers | ||||
| (a) Gelatin microgels | EGFP | PEG (1.9–12.5 kDa) + gelatin (0.03–100 kDa) | The EGFP was encapsulated in the gelatin microgels owing to the electrostatic attraction between gelatin and EGFP | 22 |
| (b) Gelatin methacrylate microparticles | FGF2 | PEG (7.3–9.3 kDa) + gelatin | The FGF2 was well loaded and exerted good therapeutic effects | 100 |
| (c) HES-HEMA microparticles | Lysozyme | PEG + HES-HEMA | Lysozyme-loaded microparticles released in vitro for more than 4 months | 101 |
| (d) CMCH microparticles | Naproxen and ropivacaine | PEG (10 kDa) + CMCH | The microparticles delivering drugs can be embedded in the thermosensitive hydrogels to achieve drug delivery for local wound | 102 |
| (e) CMCH microparticles | Calcium ions, polymerized dopamine | PEG (10 kDa) + CMCH | Possessing potential for rapid hemostasis | 103 |
| (2) Synthetic macromolecular monomers | ||||
| (a) PEG-CaM-PEG microparticles | VEGF, BMP-2 | PEG-CaM-PEG + raffinose + Ca2+ | Possessing high encapsulation efficiencies and releasing drugs at a predetermined time | 104 |
| (b) Macromonomers hydrogel microparticles | BSA and lysozyme | Norbornene- and thiol-modified four- and eight-armed poly (ethylene glycol) (10 kDa) + DEX (100–200 kDa) | Inhalable controlled drugs release system evading alveolar macrophages | 105 |